Hugh Jarrett

845 total citations
15 papers, 291 citations indexed

About

Hugh Jarrett is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Hugh Jarrett has authored 15 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 4 papers in Surgery and 4 papers in Oncology. Recurrent topics in Hugh Jarrett's work include Lung Cancer Treatments and Mutations (5 papers), Peripheral Artery Disease Management (3 papers) and Vascular Procedures and Complications (2 papers). Hugh Jarrett is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Peripheral Artery Disease Management (3 papers) and Vascular Procedures and Complications (2 papers). Hugh Jarrett collaborates with scholars based in United Kingdom, Ireland and United States. Hugh Jarrett's co-authors include James P. Halper, Jason H. Huang, Marvin H. Berman, Gareth Bate, Lazaros Andronis, Jonathan J Deeks, Smitaa Patel, Margaret Grant, Andrew W. Bradbury and Matthew Popplewell and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Thorax.

In The Last Decade

Hugh Jarrett

12 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hugh Jarrett United Kingdom	5	151	137	92	37	31	15	291
Harrie Kurvers Netherlands	13	169 1.1×	253 1.8×	38 0.4×	19 0.5×	29 0.9×	16	494
Nikolaos Karatzas Greece	9	77 0.5×	47 0.3×	49 0.5×	26 0.7×	13 0.4×	24	300
Joost P. Kerklaan Netherlands	4	67 0.4×	44 0.3×	57 0.6×	62 1.7×	27 0.9×	5	380
Risako Yamamoto Japan	12	108 0.7×	44 0.3×	32 0.3×	7 0.2×	30 1.0×	29	383
Tommaso Volpi Italy	9	156 1.0×	74 0.5×	64 0.7×	7 0.2×	10 0.3×	26	246
Ufuk Şener Türkiye	9	67 0.4×	20 0.1×	42 0.5×	53 1.4×	23 0.7×	39	294
Yixiu Liang China	14	82 0.5×	24 0.2×	44 0.5×	25 0.7×	20 0.6×	41	692
Lucio Santangelo Italy	17	148 1.0×	40 0.3×	109 1.2×	6 0.2×	48 1.5×	52	823
Maria Iamele Italy	10	58 0.4×	141 1.0×	31 0.3×	11 0.3×	19 0.6×	24	300
Yo Iwata Japan	9	124 0.8×	98 0.7×	22 0.2×	14 0.4×	21 0.7×	30	250

Countries citing papers authored by Hugh Jarrett

Since Specialization

Citations

This map shows the geographic impact of Hugh Jarrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Jarrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Jarrett more than expected).

Fields of papers citing papers by Hugh Jarrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugh Jarrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Jarrett. The network helps show where Hugh Jarrett may publish in the future.

Co-authorship network of co-authors of Hugh Jarrett

This figure shows the co-authorship network connecting the top 25 collaborators of Hugh Jarrett. A scholar is included among the top collaborators of Hugh Jarrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugh Jarrett. Hugh Jarrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Smith, Matthew E., Deborah Vickers, David R. White, et al.. (2024). Protocol for a multicentre randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss: The STARFISH trial. PLoS ONE. 19(2). e0290480–e0290480. 1 indexed citations

Moakes, Catherine A, Andrew W. Bradbury, Gareth Bate, et al.. (2024). Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT. Health Technology Assessment. 28(65). 1–72. 1 indexed citations

Ogollah, Reuben, William Hollingworth, Nicola Mills, et al.. (2024). Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren’s contractures of the fingers (Hand-2): study protocol for a randomised controlled trial. Trials. 25(1). 398–398.

Ives, Natalie, Rebecca Woolley, Moin A. Saleem, et al.. (2024). Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT. SHILAP Revista de lepidopterología. 1–78. 1 indexed citations

Mehta, Rajnikant, Hugh Jarrett, Sue Jowett, et al.. (2023). Phase III, two arm, multi-centre, open label, parallel-group randomised designed clinical investigation of the use of a personalised early warning decision support system to predict and prevent acute exacerbations of chronic obstructive pulmonary disease: ‘Predict & Prevent AECOPD’ – study protocol. BMJ Open. 13(3). e061050–e061050. 1 indexed citations

Shelley, Ben, Andreas Göebel, Louise Jackson, et al.. (2023). Study protocol for a randomised controlled trial to investigate the effectiveness of thoracic epidural and paravertebral blockade in reducing chronic post-thoracotomy pain: 2 (TOPIC 2). Trials. 24(1). 748–748.

Ferry, David, Lucinda Billingham, Hugh Jarrett, et al.. (2017). Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer. 83. 302–312. 15 indexed citations

Berman, Marvin H., et al.. (2017). Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. Journal of Neurology and Neuroscience. 8(1). 113 indexed citations

Hunt, Benjamin, Matthew Popplewell, Huw Davies, et al.. (2017). BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. Trials. 18(1). 224–224. 44 indexed citations

10.

Popplewell, Matthew, Huw Davies, Hugh Jarrett, et al.. (2016). Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials. 17(1). 11–11. 100 indexed citations

11.

Ferry, D., Lucinda Billingham, Hugh Jarrett, et al.. (2011). S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax. 66(Suppl 4). A41–A41. 8 indexed citations

12.

Billingham, Lucinda, Piers Gaunt, Hugh Jarrett, et al.. (2011). S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. Thorax. 66(Suppl 4). A41–A41. 4 indexed citations

13.

Dunlop, David J., D. Ferry, Hugh Jarrett, et al.. (2011). S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes. Thorax. 66(Suppl 4). A41–A42.

14.

Woll, Penella J., Hugh Jarrett, & Lucinda Billingham. (2011). 121 STOMP: Small cell lung cancer trial of olaparib (AZD2281) as maintenance programme - a randomised, double blind, multicentre NCRN phase II trial. Lung Cancer. 71. S42–S42. 1 indexed citations

15.

Jarrett, Hugh, et al.. (2011). S88 Day case cisplatin delivery for advanced NSCLC patients: faster, cheaper, more desirable. Thorax. 66(Suppl 4). A42–A42. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact